US EditionNew Challenge for Research in the Ozempic Era: Avoiding the Drug's Rebound Effect
5 Articles
5 Articles
Quitting Ozempic Is a Risky Proposition
Ozempic and Wegovy drugs may seem like a quick road to weight loss, but doctors say that short-term framing can be a problem. The Wall Street Journal presents a slew of metrics that show the standout benefits of GLP-1s are quickly reversed once they're no longer taken: Almost 1 in...
No one discusses the revolution that drugs like Ozempic, Wegovy or Mounjaro have meant to fight obesity. Although there are many voices that remember that these drugs are not the panacea and that, as recent studies point out, those tens of kilos eliminated come back over time, the reality is that they have opened a huge door to millions of people distressed by the excess of weight and the discrimination that this entails. And this revolution wil…
Obesity research is entering a new stage. After the pharmacological revolution, experts now focus on the sustainability of weight loss and treatment customization. That is the real challenge, they say. Therefore, it is believed that 2026 will be a key year to better understand the biology of weight reganance – the so-called 'rebound effect' observed after suspending medication (antiobesity drugs), nutritional treatments (diets) and even bariatri…
Although the drug has gained worldwide fame for its effectiveness, the specialist warned that it should not be seen as a miracle cure, but as a medical aid that requires strict supervision to avoid health problems and the inevitable "rebound." The use of this medication, originally designed for patients with diabetes, generates a feeling of early satiety by sustainably mimicking the GLP-1 hormone.
06:00 To prevent abuse, reimbursement for diabetes medications like Ozempic—which is also used for weight loss—is being tightened. From now on, health insurance funds must approve it. But the...
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
